Cover Image
市場調查報告書

AtheroNova Inc.的產品平台分析

AtheroNova Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321344
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
AtheroNova Inc.的產品平台分析 AtheroNova Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月26日 內容資訊: 英文 32 Pages
簡介

AtheroNova Inc.是總公司設置於美國的生物科技企業,正在進行安全縮小動脈硬化性斑塊的改善血脂化合物之研究開發。該公司擁有專利的化合物AHRO-001,設計為可深解動脈壁內的斑塊,透過一般代謝管道安全地排出體外。

本報告提供AtheroNova Inc. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

AtheroNova Inc. 的基本資料

  • AtheroNova Inc. 概要
  • 主要資訊
  • 企業資料

AtheroNova Inc. :R&D概要

  • 主要的治療範圍

AtheroNova Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

AtheroNova Inc. :開發中產品概況

  • 臨床階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式
  • ■AtheroNova Inc. :藥物簡介
  • AHRO-001
  • AHRO-002
  • AHRO-003
  • AHRO-010
  • AHRO-100
  • AHRO-200
  • AHRO-300

AtheroNova Inc. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

AtheroNova Inc. :最新的開發平台資訊

AtheroNova Inc. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07445CDB

Summary

Global Markets Direct's, 'AtheroNova Inc. - Product Pipeline Review - 2015', provides an overview of the AtheroNova Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AtheroNova Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of AtheroNova Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of AtheroNova Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the AtheroNova Inc.'s pipeline products

Reasons to buy

  • Evaluate AtheroNova Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of AtheroNova Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the AtheroNova Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of AtheroNova Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of AtheroNova Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of AtheroNova Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • AtheroNova Inc. Snapshot
    • AtheroNova Inc. Overview
    • Key Information
    • Key Facts
  • AtheroNova Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • AtheroNova Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • AtheroNova Inc. - Pipeline Products Glance
    • AtheroNova Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • AtheroNova Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • AtheroNova Inc. - Drug Profiles
    • AHRO-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AHRO-002
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AHRO-003
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AHRO-010
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AHRO-100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AHRO-200
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AHRO-300
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • AtheroNova Inc. - Pipeline Analysis
    • AtheroNova Inc. - Pipeline Products by Target
    • AtheroNova Inc. - Pipeline Products by Route of Administration
    • AtheroNova Inc. - Pipeline Products by Molecule Type
    • AtheroNova Inc. - Pipeline Products by Mechanism of Action
  • AtheroNova Inc. - Recent Pipeline Updates
  • AtheroNova Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • AtheroNova Inc., Key Information
  • AtheroNova Inc., Key Facts
  • AtheroNova Inc. - Pipeline by Indication, 2015
  • AtheroNova Inc. - Pipeline by Stage of Development, 2015
  • AtheroNova Inc. - Monotherapy Products in Pipeline, 2015
  • AtheroNova Inc. - Phase II, 2015
  • AtheroNova Inc. - Phase I, 2015
  • AtheroNova Inc. - Preclinical, 2015
  • AtheroNova Inc. - Discovery, 2015
  • AtheroNova Inc. - Pipeline by Target, 2015
  • AtheroNova Inc. - Pipeline by Route of Administration, 2015
  • AtheroNova Inc. - Pipeline by Molecule Type, 2015
  • AtheroNova Inc. - Pipeline Products by Mechanism of Action, 2015
  • AtheroNova Inc. - Recent Pipeline Updates, 2015
  • AtheroNova Inc., Subsidiaries

List of Figures

  • AtheroNova Inc. - Pipeline by Top 10 Indication, 2015
  • AtheroNova Inc. - Pipeline by Stage of Development, 2015
  • AtheroNova Inc. - Monotherapy Products in Pipeline, 2015
  • AtheroNova Inc. - Pipeline by Top 10 Route of Administration, 2015
  • AtheroNova Inc. - Pipeline by Top 10 Molecule Type, 2015
Back to Top